to-BBB; drug delivery to the brain

to-BBB technologies BV

to-BBB is a Dutch biotechnology company in the field of enhanced drug delivery across the blood-brain barrier.

to-BBB’s vision is that the treatment of currently unserved brain diseases will be best achieved by safely enhancing the blood-to-brain delivery of drugs.

The company is developing novel treatments for devastating brain disorders by combining existing drugs with its proprietary brain delivery platform.

LATEST NEWS:

- FDA grants Orphan Drug Status for to-BBB’s lead product, August 23

- to-BBB featured in the Neurotech Insights issue focus on blood-brain barrier, August 01

- to-BBB receives positive opinion for Orphan Drug Designation, June 14

- to-BBB announces brain drug delivery pilot study with Janssen Pharmaceutica NV for CNS diseases, May 20

- to-BBB and GSK to collaborate on brain delivery of a biologic product, March 03

PIPELINE:

FACT SHEETS:

Please see the corporate factsheet and the G-Technology factsheet for an overview of to-BBB and its core technology platform.

LATEST PRESS RELEASE:

Download here our latest press release.

MEDIA COVERAGE:

To find the latest coverage of to-BBB in the media, please click here.

(photo: Aad van Vliet / TwoMoves)